Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...
The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...
As it did during the COVID-19 pandemic, mRNA technology offers an efficient way forward in developing products for diseases ...
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...
As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback